Over the last years, genetic studies have greatly improved our knowledge on the receptor subtypes mediating various pharmacological effects of positive allosteric modulators at GABA A receptors. This stimulated the development of new benzodiazepine (BZ)-like ligands, especially those inactive/low-active at GABA A receptors containing the α 1 subunit, with the aim of generating more selective drugs. Hereby, the affinity and efficacy of four recently synthesized BZ site ligands: SH-053-2′N, SH-053-S-CH3-2′F, SH-053-R-CH3-2′F and JY-XHe-053 were assessed. They were also studied in behavioral tests of spontaneous locomotor activity, elevated plus maze, and water maze in rats, which are considered predictive of, respectively, the sedative, anxiolytic, and amnesic influence of BZs. The novel ligands had moderately low to low affinity and mild to partial agonistic efficacy at GABA A receptors containing the α 1 subunit, with variable, but more pronounced efficacy at other BZ-sensitive binding sites. While presumably α 1 receptor-mediated sedative effects of GABA A modulation were not fully eliminated with any of the ligands tested, only SH-053-2′N and SH-053-S-CH3-2′F, both dosed at 30 mg/kg, exerted anxiolytic effects. The lack of clear anxiolytic-like activity of JY-XHe-053, despite its efficacy at α 2 -and α 3 -GABA A receptors, may have been partly connected with its preferential affinity at α 5 -GABA A receptors coupled with weak agonist activity at α 1 -containing subtypes. The memory impairment in water-maze experiments, generally reported with BZ site agonists, was completely circumvented with all four ligands. The results suggest that a substantial amount of activity at α 1 GABA A receptors is needed for affecting spatial learning and memory impairments, while much weaker activity at α 1 -and α 5 -GABA A receptors is sufficient for eliciting sedation.
Introduction
The benzodiazepines (BZs) have been widely used for half a century for several neuropsychiatric disorders. They are positive allosteric modulators of the BZ binding site at GABA A receptors in the central nervous system. This site is located at the interface of an α and a γ2 subunit of a GABA A receptor usually composed of 1γ and 2α and 2β subunits. BZs act through those populations of GABA A receptors which contain an α 1 , α 2 , α 3 or α 5 subunit adjacent to the γ 2 subunit (α1 receptors, α2 receptors, etc), and by that exert anxiolytic, sedative, hypnotic, muscle relaxant, anticonvulsive and amnesic effects (reviewed in Sieghart and Ernst, 2005) . Although the second α subunit of the receptor might be of the same or a different subunit type, according to current knowledge it does not play a role in benzodiazepine pharmacology since it does not form the interface with the γ2 subunit (Minier and Sigel, 2004) .
In regard to the treatment of anxiety disorders, which has been the most extensive field of application of BZs, their continuous use as firstchoice anxiolytics has been repeatedly discouraged in the pertinent guidelines (e. Abbreviations: ß-CCt, beta-carboline-3-carboxylate-t-butyl ester; BZ, benzodiazepine; cDNA, complementary deoxyribonucleic acid; cRNA, complementary ribonucleic acid; E, east; EC 3 , molar concentration of an agonist that produces 3% of the maximal possible effect of that agonist; EPM, elevated plus maze; GABA A , gamma-aminobutyric acid type A receptor; HEK, human embryonic kidney cell; HEPES, 2-[4-(2-hydroxyethyl)-l-piperazinyl]-ethanesulfonic acid; K i , equilibrium dissociation constant of a ligand determined in inhibition studies; MB, Barths' Medium; NW, North-west; S, South; W, West; XR, Xenopus Ringer solution.
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